Search research articles
Contact Us
Filters
Showing results (41-50 of 216) with videos related to
Page
of 22
Sort By:
Brain : a Journal of Neurology
|
August 23, 2008
Benign childhood focal epilepsies: assessment of established and newly recognized syndromes
Chrysostomos P Panayiotopoulos, Michael Michael, Sue Sanders, et al.
Investigational New Drugs
|
November 13, 2008
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
Michael Michael, Peter Gibbs, Robert Smith, et al.
ANZ Journal of Surgery
|
October 14, 2014
Neoadjuvant <sup>90</sup> Yttrium peptide receptor radionuclide therapy for advanced rectal neuroendocrine tumour: a case report
Jennifer Ryan, Timothy Akhurst, A Craig Lynch, et al.
ACS Nano
|
September 20, 2017
Bridging Bio-Nano Science and Cancer Nanomedicine
Mattias Björnmalm, Kristofer J Thurecht, Michael Michael, et al.
Clinical Endocrinology
|
March 24, 2025
Approach to the Management of Gastrointestinal Manifestations in Patients With Phaeochromocytoma and Paraganglioma
Monica Majumder, Cherie Chiang, Grace Kong, et al.
ANZ Journal of Surgery
|
March 5, 2020
Colorectal peritoneal metastases: pathogenesis, diagnosis and treatment options - an evidence-based update
Vignesh Narasimhan, Geraldine Ooi, Michael Michael, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 24, 2020
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on <sup>68</sup>Ga-DOTATATE PET/CT and <sup>18</sup>F-FDG PET/CT
Lamiaa Zidan, Amir Iravani, Grace Kong, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 7, 2010
177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
Daniel Hubble, Grace Kong, Michael Michael, et al.
Asia-Pacific Journal of Clinical Oncology
|
April 14, 2021
Real-world management and patient perspectives on QOL with neuroendocrine tumors: An ANZ perspective
Michael Michael, Lorraine Chantrill, Timothy Price, et al.
Journal of Neuroendocrinology
|
November 9, 2024
Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers
Grace Kong, Geertje Noe, Cherie Chiang, et al.
Page
of 22
Search research articles
Search
Showing results (41-50 of 216) with videos related to
Sort By:
Page
of 22
Brain : a Journal of Neurology
|
August 23, 2008
Benign childhood focal epilepsies: assessment of established and newly recognized syndromes
Chrysostomos P Panayiotopoulos, Michael Michael, Sue Sanders, et al.
Investigational New Drugs
|
November 13, 2008
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer
Michael Michael, Peter Gibbs, Robert Smith, et al.
ANZ Journal of Surgery
|
October 14, 2014
Neoadjuvant <sup>90</sup> Yttrium peptide receptor radionuclide therapy for advanced rectal neuroendocrine tumour: a case report
Jennifer Ryan, Timothy Akhurst, A Craig Lynch, et al.
ACS Nano
|
September 20, 2017
Bridging Bio-Nano Science and Cancer Nanomedicine
Mattias Björnmalm, Kristofer J Thurecht, Michael Michael, et al.
Clinical Endocrinology
|
March 24, 2025
Approach to the Management of Gastrointestinal Manifestations in Patients With Phaeochromocytoma and Paraganglioma
Monica Majumder, Cherie Chiang, Grace Kong, et al.
ANZ Journal of Surgery
|
March 5, 2020
Colorectal peritoneal metastases: pathogenesis, diagnosis and treatment options - an evidence-based update
Vignesh Narasimhan, Geraldine Ooi, Michael Michael, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
June 24, 2020
Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on <sup>68</sup>Ga-DOTATATE PET/CT and <sup>18</sup>F-FDG PET/CT
Lamiaa Zidan, Amir Iravani, Grace Kong, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 7, 2010
177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide
Daniel Hubble, Grace Kong, Michael Michael, et al.
Asia-Pacific Journal of Clinical Oncology
|
April 14, 2021
Real-world management and patient perspectives on QOL with neuroendocrine tumors: An ANZ perspective
Michael Michael, Lorraine Chantrill, Timothy Price, et al.
Journal of Neuroendocrinology
|
November 9, 2024
Assessment of response to PRRT including anatomical and molecular imaging as well as novel biomarkers
Grace Kong, Geertje Noe, Cherie Chiang, et al.
Page
of 22